Idioma:

The effects of adjuvant endocrine therapy on bone health in women with breast cancer

Ramchand, Sabashini K ; Cheung, Yee-Ming ; Yeo, Belinda ; Grossmann, Mathis

Journal of endocrinology, 2019-06, Vol.241 (3), p.R111-R124 [Periódico revisado por pares]

England: Bioscientifica Ltd

Texto completo disponível

Citações Citado por

Enviar para

Título:
The effects of adjuvant endocrine therapy on bone health in women with breast cancer
Autor: Ramchand, Sabashini K ; Cheung, Yee-Ming ; Yeo, Belinda ; Grossmann, Mathis
Assuntos: Adult ; Aged ; Antineoplastic Agents, Hormonal - adverse effects ; Aromatase Inhibitors - adverse effects ; Bone and Bones - drug effects ; Bone Density - drug effects ; Breast Neoplasms - complications ; Breast Neoplasms - drug therapy ; Chemotherapy, Adjuvant ; Endocrine System - drug effects ; Endocrine System - physiology ; Estradiol ; Female ; Humans ; Middle Aged ; Postmenopause ; Practice Guidelines as Topic ; Premenopause ; Receptors, Estrogen - metabolism ; Review ; Risk Assessment ; Selective Estrogen Receptor Modulators - adverse effects ; Tamoxifen - therapeutic use
É parte de: Journal of endocrinology, 2019-06, Vol.241 (3), p.R111-R124
Notas: ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
Descrição: In women with oestrogen receptor (ER)-positive early breast cancer, oestradiol is important for breast cancer development and progression. Endocrine therapy prevents the deleterious effects of oestradiol in breast tissue by systemically depleting oestradiol concentration (aromatase inhibitors) or preventing its local action in breast tissue (selective oestrogen receptor modulators i.e. tamoxifen), thereby improving oncological outcomes. Use of aromatase inhibitors in postmenopausal women and ovarian function suppression with either tamoxifen or aromatase inhibition in premenopausal women, consequent to systemic oestradiol depletion, exerts detrimental effects on skeletal health. The oestradiol-deficient state causes increased bone remodelling and a negative bone balance. This results in bone loss, microstructural deterioration and bone fragility predisposing to fractures. Similar effects are also seen with tamoxifen in premenopausal women. In contrast, use of tamoxifen in postmenopausal women appears to exert protective effects on bone but studies on fracture risk are inconclusive. The longevity of women with ER-positive breast cancer treated with adjuvant endocrine therapy emphasises the need to mitigate the adverse skeletal effects of these therapies in order to maximise benefit. In general, fractures are associated with increased morbidity, mortality and are a high socioeconomic burden. Whilst the efficacy of antiresorptive therapy in preventing bone mineral density loss in postmenopausal women has been established, further clinical trial evidence is required to provide guidance regarding fracture risk reduction, when to initiate and stop treatment, choice of agent and optimal management of bone health in premenopausal women receiving endocrine therapy. In addition, potential oncological benefits of antiresorptive therapies will also need to be considered.
Editor: England: Bioscientifica Ltd
Idioma: Inglês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

The effects of adjuvant endocrine therapy on bone health in women with breast cancer

Ramchand, Sabashini K ; Cheung, Yee-Ming ; Yeo, Belinda ; Grossmann, Mathis

England: Bioscientifica Ltd

Buscando em bases de dados remotas. Favor aguardar.